Oct 7 (Reuters) - Merck (MRK.N), opens new tab is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off competition, a ...
Forbes contributors publish independent expert analyses and insights. I delve into the intricate workings of artificial intelligence. When an individual files a medical insurance claim, they expect ...
Merck is kicking its Keytruda-related clash with Johns Hopkins University (JHU) up a notch by asking the U.S. Patent and Trademark Office (PTO) to weigh in following a 2022 complaint. The drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback